United Kingdom: Life Sciences, Biotechnology & Nanotechnology

The World has changed; we can be certain that in an age where generative AI has become readily available to scientists, engineers and creatives, the prospects for potential leaps in innovation seem boundless.

This monthly roundup examines critical patent law developments across multiple jurisdictions, including landmark UPC Court of Appeal decisions on preliminary injunctions and urgency requirements, French and Belgian court rulings on supplementary protection certificates and biosimilar equivalence, and UK guidance on expedition applications in pharmaceutical patent disputes. The analysis explores how courts are interpreting infringement standards, evidence production alignment in parallel proceedings, and the

Artificial intelligence, wearable devices and at-home diagnostics are revolutionizing personal health management in 2026. From AI-driven health systems that create digital twins to smart rings monitoring physiological signals and home diagnostic tools tracking biomarkers, technology is enabling unprecedented personalization in wellness.

The upcoming UK general election on 4 July 2024 represents a pivotal moment for the healthcare and life sciences sectors. Stakeholders in the Life Sciences sector have been looking for policies that could address the impact of Brexit and provide a regulatory landscape to encourage innovation, in particular in the area of the use of artificial intelligence (AI) in medical technologies.

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

The growing use of combination therapies pairing small molecules with biologics is reshaping drug development, delivering clinically meaningful synergy and improved efficacy. However, as the science advances, so do the intellectual property and regulatory challenges, particularly where multiple stakeholders are involved in bringing these therapies to market.

The Patent Mediation and Arbitration Centre (PMAC), the Unified Patent Court’s (UPC's) specialist alternative dispute resolution (ADR) body, has published model ADR clauses and submission agreements...

On 11 May 2026, the Medicines and Healthcare products Regulatory Agency (“MHRA”) opened a call for evidence on proposed changes to pre-market medical device and in vitro diagnostic medical device (“IVD”)...

The space sector is going through an exciting period of development and innovation – it is cheaper than ever to put mass into orbit, a record number of satellites are orbiting our planet...